Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bile duct disorders.

André P Geubel1, Christine Sempoux, Jacques Rahier

  • 1Department of Gastroenterology, St. Luc University Hospital, Université Catholique de Louvain 10, Avenue Hippocrate, 1200 Brussels, Belgium. geubel@gaen.ucl.ac.be

Clinics in Liver Disease
|July 26, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A multisociety consensus statement on a new common definition and diagnostic criteria for PSVD or NCPF.

Hepatology international·2026
Same author

Increasing Case Numbers and Earlier Age at Diagnosis of Alveolar Echinococcosis: Insights from a 13-Year Retrospective Swiss Study.

Pathogens (Basel, Switzerland)·2026
Same author

A multisociety consensus statement on a new common definition and diagnostic criteria for PSVD or NCPF.

Hepatology (Baltimore, Md.)·2026
Same author

A multisociety consensus statement on a new common definition and diagnostic criteria for PSVD or NCPF.

Annals of hepatology·2026
Same author

A multisociety consensus statement on a new common definition and diagnostic criteria for PSVD or NCPF.

Journal of hepatology·2026
Same author

New histopathological terminology for well-differentiated hepatocellular lesions in unusual clinico-pathological scenarios: HCA-like and FNH-like.

JHEP reports : innovation in hepatology·2026
Same journal

Metabolic Dysfunction-Associated Steatohepatitis: From Fibrosis-Based Risk Stratification to Emerging Therapeutic Strategies.

Clinics in liver disease·2026
Same journal

Metabolic Dysfunction-Associated Steatotic Liver Disease and Viral Hepatitis.

Clinics in liver disease·2026
Same journal

Metabolic Dysfunction Associated Steatohepatitis (MASH) in Oceania, Central America, and the Caribbean.

Clinics in liver disease·2026
Same journal

Metabolic Dysfunction-Associated Steatotic Liver Disease in Latin America.

Clinics in liver disease·2026
Same journal

Metabolic Dysfunction-Associated Steatotic Liver Disease in Africa: From Burden to Action.

Clinics in liver disease·2026
Same journal

Metabolic Dysfunction-Associated Steatotic Liver Disease in Asia: Epidemiology, Clinical Features, and Management.

Clinics in liver disease·2026
See all related articles

Drug-induced cholestasis, a common side effect, may be increasing due to newer medications. Early intervention in vanishing bile duct syndrome shows promise, though treatment remains challenging.

Area of Science:

  • Hepatology
  • Clinical Pharmacology

Background:

  • Drug-induced bile duct injury can cause prolonged or chronic cholestasis.
  • Increased reports may reflect true incidence rise and greater awareness of drug-induced vanishing bile duct syndrome.
  • Diagnostic challenges arise due to varied presentations, delayed onset post-therapy, and potential misdiagnosis as idiopathic ductopenia.

Purpose of the Study:

  • To review the clinical presentation, diagnostic difficulties, and potential origins of drug-induced bile duct injury.
  • To explore the unknown pathogenesis and prognostic factors of vanishing bile duct syndrome.
  • To discuss current therapeutic strategies and their limitations.

Main Methods:

  • Review of clinical presentations and diagnostic challenges.
  • Discussion of potential pathogenetic factors, including genetics (HLA-dependent predisposition).

Related Experiment Videos

  • Analysis of therapeutic outcomes for large and small bile duct injuries.

    • Main Results:

    • Drug-induced cholestasis presents diverse features, complicating diagnosis, especially when symptoms appear after drug cessation.
    • Genetic factors likely play a role in predisposition, alongside other unknown contributors.
    • Current treatments for small bile duct injury are largely ineffective, with ursodeoxycholic acid showing unpredictable efficacy.

    Conclusions:

    • Some cases of idiopathic adulthood ductopenia may stem from overlooked drug-induced vanishing bile duct syndrome.
    • Early therapeutic intervention in vanishing bile duct syndrome may improve outcomes.
    • Further longitudinal studies are needed to clarify prognostic determinants and optimize treatment.